Login to Your Account



PIPELINE UPDATE OR NEGOTIATION TACTIC?

Astrazeneca presents case for defense, as Sweden voices concerns on Pfizer bid

By Cormac Sheridan
Staff Writer

Wednesday, May 7, 2014

Pascal Soriot, CEO of Astrazeneca plc, and his senior management team came out fighting against Pfizer Inc.'s takeover bid Tuesday, setting out an ambitious long-term growth plan for the company based on current growth drivers and a rapidly maturing pipeline which, they claim, will lead to $45 billion in revenue by 2023.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription